J Appl Biotechnol Rep. 2026 March;13(1):1990-1992

doi 10.30491/jabr.2025.557020.1938

Journal of
Applied Biotechnology Reports

Commentary

SATB2–Ki67 Axis: Toward Artificial Intelligence-Enhanced Prognostic Models in Colorectal Cancer

Piruz Shadbash [1, 2*], Marzieh Bahari Babadi [3]

[1] Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
[2] Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
[3] Department of Biochemistry, Medical School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Corresponding Author: Piruz Shadbash, PhD Candidate, Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: +989032670910, E-mail: shadbashpiruz@gmail.com

Received November 2, 2025; **Accepted** November 11, 2025; **Online Published** March 30, 2026

Abstract
The convergence of molecular pathology and artificial intelligence (AI) has begun redefining prognostic assessment in colorectal cancer (CRC). The recent study by Kareem et al. (2025) in the Journal of Applied Biotechnology Reports underscores the prognostic potential of combined SATB2 and Ki67 expression in predicting progression-free survival among CRC patients. Beyond its biomarker significance, the SATB2–Ki67 axis embodies a paradigm shift in digital oncology, linking chromatin architecture and cellular proliferation with image-based analytics and computational modeling. This commentary discusses how integrating immunohistochemical (IHC) signatures of SATB2 and Ki67 into AI-driven histopathological platforms could transform CRC prognostication, enabling precision risk stratification, digital biomarker scoring, and personalized therapeutic guidance. We further explore how deep learning algorithms, multiplex IHC, and radiogenomic data fusion could optimize SATB2–Ki67–based predictive models for next-generation oncology practice.
Keywords: Colorectal Cancer, SATB2, Ki67, Artificial Intelligence, Digital Oncology
Citation: Shadbash P, Bahari Babadi M. SATB2–Ki67 Axis: Toward Artificial Intelligence-Enhanced Prognostic Models in Colorectal Cancer. J Appl Biotechnol Rep. 2025;13(1):1990-1992. doi:10.30491/jabr.2025.557020.1938

Introduction

Colorectal cancer (CRC) remains one of the leading global causes of cancer-related mortality, driven by intertumoral heterogeneity and late-stage diagnosis.[1] Although molecular profiling has transformed CRC classification into distinct genomic and epigenomic subtypes, histopathological evaluation remains the clinical gold standard.[2] Immunohistochemical (IHC) biomarkers such as Ki67, a marker of proliferative index, and SATB2, a transcriptional regulator of chromatin remodeling, have emerged as powerful indicators of tumor differentiation and patient prognosis.[3] In a 2025 cohort study, Kareem et al. demonstrated that co-expression of SATB2 and Ki67 can stratify CRC patients by progression-free survival, offering superior prognostic power compared to traditional TNM staging alone.[4] Notably, increased SATB2 correlated with favorable outcomes, whereas high Ki67 predicted poor survival. The inverse relationship between these markers highlights the interplay between epigenetic regulation and proliferation in colorectal tumor biology. However, manual interpretation of such biomarkers is inherently subjective, limited by inter-observer variability and spatial sampling bias. Artificial intelligence (AI), particularly deep learning applied to whole-slide images, offers a transformative pathway for extracting reproducible, quantitative prognostic features from histopathology.[5] Integrating SATB2–Ki67 expression into AI-enhanced workflows could yield highly accurate, automated models for predicting disease progression, response to therapy, and survival outcomes.

SATB2 and Ki67 as Digital Biomarkers in CRC

SATB2 (Special AT-rich Sequence-Binding Protein 2) is a nuclear matrix-associated transcription factor involved in chromatin organization and gene regulation.[6] It serves as a lineage-specific marker for colorectal epithelial cells and has been proposed as a differential diagnostic biomarker distinguishing CRC from non-colorectal adenocarcinomas. Ki67, by contrast, reflects proliferative activity and serves as a quantitative measure of tumor aggressiveness.[7] The dual assessment of these markers offers complementary biological insights: SATB2 denotes differentiation potential and epigenetic stability, whereas Ki67 indicates proliferative drive. The integration of these two IHC stains, when digitized, provides an ideal substrate for computational pathology. High-resolution image data of SATB2 and Ki67 slides can be transformed into numerical features, including nuclear density, staining intensity, texture, and spatial co-localization, allowing AI algorithms to learn prognostic patterns invisible to the human eye.

AI-Augmented Prognostic Modeling in CRC

AI-based pathology models employ convolutional neural networks (CNNs) and graph-based learning to extract morphological and molecular correlates from digitized slides.[8] When trained on large annotated datasets, these models can identify cellular features associated with outcomes such as recurrence, metastasis, or drug resistance. Integrating SATB2 and Ki67 data into AI pipelines could refine these prognostic models in several ways:

1. Automated Quantification: Deep learning can quantify nuclear staining across large tissue regions, eliminating human bias in percentage scoring of Ki67 and intensity grading of SATB2.
2. Spatial Feature Mapping: AI can map SATB2–Ki67 co-expression at the single-cell level, linking proliferative gradients with differentiation zones within the tumor microenvironment.
3. Multimodal Data Fusion: By combining IHC data with genomic, transcriptomic, or radiomic inputs, AI systems can generate composite biomarkers reflecting both phenotypic and molecular tumor states.
4. Predictive Analytics: Trained models can predict progression-free survival, therapeutic response, or immunotherapy sensitivity using co-expression features as key variables.

Translational and Clinical Implications

The clinical adoption of AI-assisted SATB2–Ki67 scoring could redefine CRC pathology workflows. Digitized IHC slides analyzed by validated algorithms could deliver standardized, reproducible metrics to oncologists, improving treatment stratification. High SATB2 and low Ki67 scores might identify patients who could benefit from less aggressive chemotherapy regimens, whereas the reverse profile could flag high-risk individuals requiring intensive follow-up. Additionally, AI-derived spatial maps of SATB2–Ki67 interactions could illuminate intratumoral heterogeneity, guiding sampling for molecular testing or biopsy selection. This is particularly relevant in the era of precision oncology, where heterogeneous biomarker expression can influence response to immunotherapy and targeted agents. The integration of AI in biomarker evaluation also aligns with the global shift toward computational histopathomics, where deep learning not only automates pattern recognition but also uncovers latent biological signatures that reflect tumor metabolism, immune infiltration, or stromal remodeling.

Challenges and Future Directions

While promising, several challenges must be addressed before AI-enhanced SATB2–Ki67 modeling can be translated into clinical practice:

- Data Standardization: Variability in staining protocols, scanner resolution, and image normalization can limit model generalizability.
- Sample Size and Diversity: Multi-institutional datasets are required to capture CRC's biological and demographic heterogeneity.
- Explainability: Regulatory acceptance demands transparent algorithms whose decision pathways are biologically interpretable.
- Integration with Genomics: The ultimate goal is a multimodal prognostic pipeline that combines digital pathology, multi-omics, and clinical data to produce a unified, interpretable risk score.

Future research should prioritize explainable AI (XAI) models capable of linking morphological biomarkers such as SATB2 and Ki67 with actionable genomic events. In addition, federated learning frameworks can facilitate collaborative model training across pathology centers without compromising data privacy. The next frontier lies in developing AI-driven virtual staining and radiogenomic fusion models, enabling prediction of SATB2–Ki67 expression directly from noninvasive imaging such as MRI or CT radiomics.

Future Perspective

The study by Kareem et al. provides a robust biological foundation for the digital evolution of CRC prognostication. By merging SATB2's chromatin-regulatory role with Ki67's proliferative index, and embedding both within AI-enhanced frameworks, oncology is moving toward a computationally integrated precision pathology model. In the coming decade, we anticipate:

- Fully automated biomarker quantification pipelines embedded in hospital information systems.
- Integration of AI-based SATB2–Ki67 scoring into national CRC screening and surveillance programs.
- Expansion of training datasets linking histopathology with multi-omics data to enable in silico clinical trials.

Ultimately, the SATB2–Ki67 axis represents more than a dual biomarker pair, it symbolizes the convergence of epigenetic biology, digital pathology, and artificial intelligence in shaping the next era of precision oncology.

Conflict of Interest Disclosures

None.

References

1. Nie JX, Xie Q, Yuan Y, Liu MY, Du JK, Li N, et al. Rising incidence of total and Early-Onset colorectal cancer: A global perspective on burden, risk factors, and projections to 2031. J Gastrointest Cancer. 2025;56(1):138. doi:10.1007/s12029-025-01257-1
2. Hoseini SH, Enayati P, Nazari M, Babakhanzadeh E, Rastgoo M, Sohrabi NB. Biomarker profile of colorectal cancer: current findings and future perspective. J Gastrointest Cancer. 2024;55(2):497-510. doi:10.1007/s12029-023-00990-9
3. Roy SK, Shrivastava A, Srivastav S, Shankar S, Srivastava RK. SATB2 is a novel biomarker and therapeutic target for cancer. J Cell Mol Med. 2020;24(19):11064-9. doi:10.1111/jcmm.15755
4. A Kareem H, Jabbar Hasan Y. Prognostic Value of Combined SATB2 and Ki67 Expression in Colorectal Cancer Patients: A Retrospective Cohort Study. J Appl Biotechnol Rep. 2025;12(2):1668-77. doi:10.30491/jabr.2025.512767.1855
5. Lee M. Recent advancements in deep learning using whole slide imaging for cancer prognosis. Bioengineering. 2023;10(8):897. doi:10.3390/bioengineering10080897
6. Cheng G, Tian C, Wang W, Zhou Y, Wang X, Zhang L. Advances in research on SATB2 and its role in tumor development. Cell Biosci. 2025;15(1):111. doi:10.1186/s13578-025-01439-1
7. Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019;491:39-45. doi:10.1016/j.cca.2019.01.011
8. Alkhalaf AK, Alkhateeb SA, Alshammari MM. Integration of artificial intelligence in histopathological and radiological image analysis: Enhancements in diagnostic workflow. Int J Health Sci. 2024;8(S1):938-53. doi:10.53730/ijhs.v8nS1.15010